公开(公告)号：US20230089126A1

公开(公告)日：2023-03-23

申请号：US17644993

申请日：2021-12-17

Applicant: Genentech, Inc.

Inventor： Sushant Malhotra ,  Jianfeng Xin ,  Steven Do ,  Jack Terrett

IPC: C07D401/14 ,  A61P35/00 ,  A61K9/00 ,  C07D405/14

Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

公开(公告)号：US20210230142A9

公开(公告)日：2021-07-29

申请号：US16679104

申请日：2019-11-08

Applicant: Genentech, Inc.

Inventor： Sushant Malhotra ,  Jianfeng Xin ,  Steven Do ,  Jack Terrett

IPC: C07D401/14 ,  C07D405/14 ,  A61P35/00 ,  A61K9/00

Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

公开(公告)号：US20140357644A1

公开(公告)日：2014-12-04

申请号：US14457582

申请日：2014-08-12

Applicant: Array BioPharma Inc. ,  Genentech, Inc.

Inventor： Josef R. Bencsik ,  James F. Blake ,  Nicholas C. Kallan ,  Ian S. Mitchell ,  Keith Lee Spencer ,  Dengming Xiao ,  Rui Xu ,  Christine Chabot ,  Steven Do ,  Jun Liang ,  Brian Safina ,  Birong Zhang

IPC: C07D239/70

CPC classification number: C07D239/70

Abstract: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.

Abstract translation: 本发明提供包含式I的化合物，包括其药学上可接受的盐：还提供使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。

公开(公告)号：US20140288047A1

公开(公告)日：2014-09-25

申请号：US14297142

申请日：2014-06-05

Applicant: Genentech, Inc.

Inventor： Nicole Blaquiere ,  Steven Do ,  Danette Dudley ,  Adrian Folkes ,  Robert Heald ,  Timothy Heffron ,  Mark Jones ,  Aleksandr Kolesnikov ,  Chudi Ndubaku ,  Alan G. Olivero ,  Stephen Price ,  Steven Staben ,  Lan Wang

IPC: C07D498/14 ,  A61K31/553 ,  A61K45/06 ,  C07D498/04

CPC classification number: C07D498/04 ,  A61K31/553 ,  A61K45/06 ,  C07D491/044 ,  C07D498/14 ,  C07D519/00

Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 式I的苯并氧氮杂化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物及其药学上可接受的盐，其中：Z1是CR1或N; Z2为CR2或N; Z3为CR3或N; Z4是CR4或N; B是与苯并氧杂环环稠合的吡唑基，咪唑基或三唑基环，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗由脂质激酶介导的癌症等疾病。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US20140005168A1

公开(公告)日：2014-01-02

申请号：US13927278

申请日：2013-06-26

Applicant: Genentech, Inc.

Inventor： Steven Do ,  Huiyong Hu ,  Aleksandr Kolesnikov ,  Vickie H. Tsui ,  Xiaojing Wang

IPC: C07D471/04 ,  A61K31/551 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/513 ,  C07D491/052 ,  A61K31/55 ,  C07D471/10 ,  C07D487/10 ,  A61K45/06 ,  A61K31/501 ,  A61K31/496 ,  A61K31/444

CPC classification number: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/513 ,  A61K31/55 ,  A61K31/551 ,  A61K45/06 ,  C07D471/10 ,  C07D487/10 ,  C07D491/052

Abstract: 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 式I的5-氮杂吲唑化合物，包括立体异构体，几何异构体，互变异构体及其药学上可接受的盐，可用于抑制Pim激酶和用于治疗由Pim激酶介导的癌症等疾病。 公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：US08586574B2

公开(公告)日：2013-11-19

申请号：US13681763

申请日：2012-11-20

Applicant: Genentech, Inc.

Inventor： Nicole Blaquiere ,  Steven Do ,  Danette Dudley ,  Adrian Folkes ,  Robert Heald ,  Timothy Heffron ,  Mark Jones ,  Aleksandr Kolesnikov ,  Chudi Ndubaku ,  Alan G. Olivero ,  Stephen Price ,  Steven Staben ,  Lan Wang

IPC: A61K31/553 ,  C07D498/04 ,  C07D498/14

CPC classification number: C07D498/04 ,  A61K31/553 ,  A61K45/06 ,  C07D491/044 ,  C07D498/14 ,  C07D519/00

Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US20240025919A1

公开(公告)日：2024-01-25

申请号：US18199449

申请日：2023-05-19

Applicant: Genentech, Inc.

Inventor： Matthew Leo Landry ,  Christian Nilewski ,  Michael Siu ,  Elisia Villemure ,  Yong Wang ,  BinQing Wei ,  Melissa Ann Ashley ,  Steven Do ,  Lewis John Gazzard ,  Samantha Alyson Green

IPC: C07D519/00 ,  C07D498/22 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D498/22

Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.

公开(公告)号：US20230002345A1

公开(公告)日：2023-01-05

申请号：US16642824

申请日：2019-08-15

Applicant: Genentech, Inc.

Inventor： Aijun LU ,  Sushant Malhotra ,  Alan G. Olivero ,  Cheng Shao ,  Yamin Zhang ,  Steven Do

IPC: C07D401/04 ,  C07D403/04 ,  C07D239/94 ,  C07D405/04 ,  C07D403/12 ,  C07D403/14 ,  C07D401/14 ,  C07D413/12 ,  C07D471/04

Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

公开(公告)号：US20220226326A1

公开(公告)日：2022-07-21

申请号：US17409644

申请日：2021-08-23

Applicant: Array BioPharma Inc. ,  Genentech, Inc.

Inventor： Ian S. Mitchell ,  James F. Blake ,  Rui Xu ,  Nicholas C. Kallan ,  Dengming Xiao ,  Keith Lee Spencer ,  Josef R. Bencsik ,  Eli M. Wallace ,  Stephen T. Schlachter ,  Anna L. Leivers ,  Jun Liang ,  Brian Safina ,  Birong Zhang ,  Christine Chabot ,  Steven Do

IPC: A61K31/517 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D239/70 ,  C07D413/12 ,  C07D407/12

Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

公开(公告)号：US10899772B2

公开(公告)日：2021-01-26

申请号：US16715997

申请日：2019-12-16

Applicant: Genentech, Inc.

Inventor： Marian C. Bryan ,  Steven Do ,  Tamiko Katsumoto ,  Jun Liang ,  Naomi S. Rajapaksa ,  James Richard Kiefer, Jr. ,  Liqiang Fu

IPC: C07D487/04 ,  C07D413/14 ,  C07D471/04 ,  C07D495/04

Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.